Option Care Health Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Option Care Health, Inc.

Kahn Swick & Foti is investigating the proposed sale of Option Care Health to CD&R and McKesson Corporation. Under the proposed terms, Option Care shareholders would receive $32.05 in cash per share; the article excerpt ends before stating what aspects of the consideration or process are under review.

Analysis

The investigation notice is not evidence that the $32.05 offer is inadequate or that a deal challenge has merit; treat it initially as headline noise, not a change in transaction value. For OPCH, the key exposure is now deal probability and timing: at or near the cash consideration, upside is bounded absent a higher bid, while a failed or delayed transaction could reopen standalone valuation risk. The relevant signal is the deal spread versus $32.05, not the investigation headline in isolation.

Over days, legal-investigation headlines may widen the spread briefly and create event-driven liquidity. Over 1–3 months, assess whether a filed complaint identifies a specific process or disclosure issue and whether it changes the shareholder timetable, agreement terms, or closing conditions. A generic investigation alone does not establish a credible path to a higher price. For MCK, the economic impact cannot be sized from this notice: verify its precise role, transaction funding and termination exposure in the merger documents before treating OPCH deal risk as material to MCK shares. Longer term, any change in ownership could affect competitive positioning in infusion services, but the article provides no basis to quantify that effect. The contrarian point: legal notices attract attention, but without substantive allegations or a measurable delay, investors may overprice the probability of a revised bid.

Key Decisions for Investors

• Do not trade OPCH solely on this announcement. First compare its price with the $32.05 cash consideration and calculate the implied spread against the expected time to close; the article supplies neither a market price nor a closing timetable.
• If OPCH trades meaningfully below consideration, treat it as a deal-risk position, not a value thesis. Consider event-driven exposure only after reviewing the merger agreement, termination provisions, closing conditions and any filed complaint; cap downside for a deal break rather than assuming a price increase.
• Keep MCK exposure neutral pending verification of its contractual role and funding obligations. Reassess if filings show material termination liability, financing commitments, or a timetable change.
• Falsifiers: a court order or credible complaint that materially impedes closing, a revised offer or agreement, or a disclosed delay in required approvals would change the deal-probability assessment. A dismissal or absence of substantive allegations with no timetable change would support treating the notice as noise.